MedTrace Logo

AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas

NCT02831257 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2022-06-13

Study results available
· View outcomes & findings →

Summary

The goal of this clinical research study is to learn if the study drug AZD2014 can shrink growing or symptomatic meningiomas.

Conditions

  • Neurofibromatosis 2
  • Meningioma

Interventions

DRUG

AZD2014

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • United States Department of Defense

    collaborator FED

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Scott Plotkin, MD, PhD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2019-05-31
Completion
2020-10-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02831257 on ClinicalTrials.gov